Next in Cell Line Development
Is Your Cell Line Development Ready for Tomorrow's Therapies?
Innovation in development processes is key to unlock the true potential of biologics. In this free seminar, see what's new in cell line development and critical quality attribute analysis methods and connect with the Dutch biopharma network over drinks.
Program
15:00 - 15:15: Walk-in
15:15 - 16:15: session 1 - putting CLD to work
16:15 - 16:30: break
16:30 - 17:30: session 2 - Innovation in CLD
17:30 - 18:00: closing drinks
Speakers
Bart Engels - ProteoNic
ProteoNic's new 2G Unic vector technology enables developers to create cell lines with superior productivity and stability, at shorter development times.
Alfred Luitjens - Almira Biotech & Batavia Biosciences
With over 40 years of experience in viral vector development manufacturing, will address the global challenges of bringing down mAb costs to under 10 USD per gram.
Guus Scheefhals - Syngle Therapeutics
10 million people worldwide are living with Parkinson’s disease, with little hope of treatment. Supported by the The Michael J. Fox Foundation for Parkinson's Research, Syngle seeks to address this pressing issue with their new biologic, a promising new antibody that targets the Parkinson’s disease-associated alphasynuclein oligomers.
Carlos de Lannoy -Constellate Proteomics
Constellate's all-in-one analysis devices allow evaluation of four critical quality attributes up to six weeks earlier in development.
In collaboration with
